Clinical trials
Amyloid Neuropathies, Familial trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 11 |
| Completed | 9 |
| Unknown status | 6 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alnylam Pharmaceuticals | 5 |
| Eidos Therapeutics, a BridgeBio company | 3 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 |
| Ionis Pharmaceuticals, Inc. | 2 |
| Pfizer | 2 |
| University of Messina | 2 |
| Boston University | 1 |
| Centro Cardiologico Monzino | 1 |
| Federico II University | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyloid Neuropathies, Familial | 27 |
| Amyloidosis | 13 |
| Cardiomyopathies | 7 |
| Alzheimer Disease | 6 |
| Amyloidosis, Familial | 5 |
| Heart Failure | 5 |
| Amyloid Neuropathies | 3 |
| Polyneuropathies | 3 |
| Cardiomyopathy, Hypertrophic | 2 |
| Fabry Disease | 2 |
Trials
Showing 76 to 27 of 27. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.